What Makes a Fertility Case Complex?
A fertility case does not become complex because of one abnormal number or one unsuccessful attempt.
Complexity may arise when several factors overlap: advanced maternal age, low ovarian reserve, severe male-factor infertility, endometriosis, adenomyosis, uterine disease, genetic risk, recurrent pregnancy loss, poor embryo development, or repeated treatment failure.
Sometimes the greatest difficulty is uncertainty. The patient may have undergone several procedures, received different explanations, and been offered multiple tests without a clear understanding of what problem each test was intended to solve.
At Jinemed, the approach to complex fertility cases begins with reconstruction rather than immediate treatment. The medical team reviews what has already happened, distinguishes evidence from assumption, and identifies which parts of the previous journey provide useful information.
Experience matters in difficult cases, but experience is not the same as promising a result. Its value lies in asking better questions, recognising patterns, avoiding unnecessary repetition, and communicating the limits of medicine honestly.
Rebuilding the Medical Story
Patients with repeated unsuccessful treatment often arrive with large medical files but an incomplete clinical story.
Before recommending another cycle, the team may need to review:
- Age and reproductive history
- Menstrual pattern and ovarian reserve testing
- Antral follicle count and ultrasound findings
- Previous stimulation protocols and medication doses
- Follicle development and hormone monitoring
- Number of eggs collected and number of mature eggs
- Fertilisation method and fertilisation rate
- Embryo development on each laboratory day
- Blastocyst formation and embryo grading
- Embryo-freezing or biopsy records
- Endometrial thickness and transfer details
- Semen analysis, sperm source, and male evaluation
- Genetic tests and pathology reports
- Pregnancy tests, biochemical pregnancies, miscarriages, and obstetric records
- Operative notes from hysteroscopy, laparoscopy, or uterine surgery
The objective is not to produce a longer list of abnormalities. It is to locate the stage at which difficulty occurred.
A cycle with few eggs presents a different problem from a cycle with many eggs but poor fertilisation. Normal fertilisation followed by embryo arrest requires a different discussion from transfer of good-quality embryos without implantation. A positive pregnancy followed by miscarriage is not the same event as failure to implant.
Accurate definition is the beginning of rational treatment.
Low AMH and Diminished Ovarian Reserve
Anti-Müllerian hormone, or AMH, is used together with ultrasound findings and clinical history to estimate ovarian reserve and likely response to stimulation.
A low AMH result may suggest that fewer follicles and eggs will be obtained during an IVF cycle. It does not directly measure the genetic quality of an egg, and it should not be interpreted as proof that pregnancy is impossible.
Age remains central. A younger woman with low AMH and an older woman with the same AMH value may have very different expectations because ovarian reserve and age-related egg quality are separate, although connected, issues.
Patients with diminished ovarian reserve need clear counselling about:
- The possibility of collecting only a small number of eggs
- The risk of cycle cancellation or no egg retrieval
- The possibility that not every egg will be mature
- The possibility of no fertilisation or no transferable embryo
- The potential need for more than one cycle
- The limits of increasing medication doses
- The role and limitations of embryo accumulation or pooling
The aim is to preserve hope without converting one or two follicles into a promise.
For some patients, obtaining one usable embryo is possible and meaningful. For others, repeated stimulation may not produce an embryo. Both possibilities should be discussed before treatment begins.
Individualising Ovarian Stimulation
There is no stimulation protocol that is best for every patient with low ovarian reserve.
Previous response, age, body weight, antral follicle count, hormone results, menstrual pattern, and the timing of follicle recruitment may influence the plan. A protocol that worked poorly once may need modification, but changing every medication without understanding the earlier response can make comparison more difficult.
More medication does not always create more follicles. The ovary can only respond with the follicles available during that cycle. Very high doses may increase cost and treatment burden without producing a proportional increase in eggs.
The medical team may instead focus on achieving the most coordinated growth possible from the available follicle group, selecting an appropriate trigger, and planning egg collection carefully.
In some cases, consecutive or repeated cycles may be discussed. The decision should consider not only biology but also emotional burden, cost, travel, and whether the accumulated information continues to justify further attempts.
Advanced Maternal Age
Age affects fertility through both the number and chromosomal competence of eggs.
As maternal age increases, ovarian reserve generally declines and a larger proportion of embryos may carry chromosomal abnormalities. This can reduce implantation, increase miscarriage risk, and make it harder to obtain a chromosomally suitable embryo.
The effect of age cannot be reversed by increasing medication, using ICSI, changing the day of transfer, or adding laboratory procedures. Treatment may help identify and use the eggs available; it cannot return the ovaries to a younger biological age.
This is one of the most difficult conversations in reproductive medicine. Patients deserve information that is neither cruel nor misleading.
Chronological age alone does not determine an individual outcome, but it strongly influences probabilities. A responsible consultation explains what treatment can attempt, what it cannot change, and how many eggs or embryos may realistically be needed to create a meaningful chance.
Embryo Accumulation and Pooling
Patients who produce only one or two embryos per cycle may consider accumulating embryos over several egg collections before transfer or genetic testing.
This strategy may be useful in selected situations, particularly when the purpose is to create a larger group for PGT or to preserve embryos before ovarian reserve declines further.
However, pooling is not automatically superior to transferring an available embryo. It requires additional stimulation cycles, expense, time, freezing, and emotional commitment. Some patients may complete several cycles and still obtain only a small number of embryos.
The decision depends on age, embryo numbers, whether PGT is planned, previous outcomes, and the patient’s priorities. The strategy should be presented as one possible pathway rather than a universal solution for low AMH.
Fertilisation Failure
When eggs are collected but none fertilise, the case requires careful laboratory review.
Questions may include:
- Were the eggs mature?
- Was conventional IVF or ICSI used?
- Were there technical difficulties during injection?
- What were the sperm findings?
- Did the eggs show signs of degeneration or abnormal activation?
- Has fertilisation failure occurred more than once?
ICSI can overcome several barriers related to sperm reaching and penetrating the egg, but it cannot guarantee fertilisation. Egg activation, egg competence, sperm factors, and rare biological problems may still prevent normal fertilisation.
After total or very low fertilisation, the team should distinguish a potentially correctable technical or timing issue from a repeated biological pattern. Additional interventions should be considered only when there is a clear rationale and an honest discussion of limited evidence.
Poor Embryo Development and Embryo Arrest
Some embryos fertilise normally but stop developing before reaching the blastocyst stage.
Embryo arrest may be influenced by egg factors, sperm factors, chromosomal abnormalities, laboratory conditions, or a combination that cannot be identified in an individual case.
Review should include the number and maturity of eggs, fertilisation findings, embryo development day by day, sperm parameters, parental age, and laboratory observations. One cycle with poor development does not always predict that every future cycle will be identical, particularly when only a small number of eggs were available.
At the same time, repeated arrest across multiple well-documented cycles is important information. Patients should not be told that a new supplement, culture medium, or unproven add-on will certainly correct the problem.
The embryology laboratory is central to this assessment, but laboratory quality should not be used as a convenient explanation for every unsuccessful cycle. Biology and laboratory performance must both be considered objectively.
Severe Male-Factor Infertility
Very low sperm count, poor motility, azoospermia, previous failed fertilisation, or high-risk male history can make an IVF case complex.
Evaluation may require urology, hormone testing, ultrasound, genetic assessment, repeat semen analysis, or surgical sperm-retrieval planning. In azoospermia, distinguishing obstruction from severe impairment of sperm production is essential.
ICSI, TESE, or micro-TESE may provide a path to treatment in selected cases, but finding sperm and achieving fertilisation cannot be guaranteed.
The female partner’s treatment should be coordinated with the male plan. Before ovarian stimulation begins, the team should consider whether sperm is already available, whether retrieval should occur in advance with freezing, or whether procedures will be synchronised.
Complex male infertility is not solved by focusing exclusively on the egg. It requires the urologist, embryologist, fertility physician, and genetic specialist to work as one team.
Repeated IVF Failure: Start with the Definition
“IVF failed” can describe several different events:
- The ovaries did not respond sufficiently
- No eggs were collected
- Eggs were collected but were immature
- Fertilisation did not occur
- Embryos stopped developing
- No embryo was suitable for transfer
- An embryo was transferred but the pregnancy test was negative
- A biochemical pregnancy occurred
- A clinical pregnancy ended in miscarriage
These outcomes should not be grouped together under one unexplained diagnosis.
Before recommending new tests, the team must determine whether the recurring problem is ovarian response, fertilisation, embryo development, implantation, or pregnancy continuation.
The next plan should target the observed problem rather than the patient’s understandable fear that “everything is wrong.”
Recurrent Implantation Failure
Recurrent implantation failure is one of the most debated areas of reproductive medicine. There is no single number of failed transfers that has the same meaning for every patient.
The interpretation depends on age, embryo stage, embryo quality, whether embryos were genetically tested, the number transferred, uterine factors, and the probability that implantation would have occurred by that point.
After repeated unsuccessful transfers, review may include:
- Embryo quality and laboratory history
- Transfer technique
- Uterine-cavity assessment
- Endometrial thickness and preparation
- Fibroids, polyps, adhesions, or congenital abnormalities
- Hydrosalpinx
- Adenomyosis or endometriosis when clinically relevant
- Hormonal and medical factors
- Whether the pattern reflects expected statistical chance rather than a new disease
The investigation should be targeted. A patient should not automatically receive every available immune test, clotting panel, biopsy, microbiome analysis, receptivity test, or experimental treatment simply because several transfers were unsuccessful.
More testing can create more ambiguous findings without revealing a treatable cause.
The Uterus and Endometrium
The uterine environment matters, but not every visible finding prevents implantation.
Fibroids should be assessed according to location and effect on the uterine cavity, not size alone. Polyps, adhesions, septa, hydrosalpinx, adenomyosis, and endometriosis may influence planning in selected patients.
Ultrasound is often the starting point. Hysteroscopy, saline sonography, MRI, or laparoscopy may be considered when symptoms, imaging, or history provide a reason.
Routine hysteroscopy before every transfer is not evidence-based. Surgery should be recommended when the expected benefit is greater than the risk, delay, cost, and potential effect on fertility.
The same principle applies to endometrial “add-ons.” A test should be ordered only if the result can be interpreted reliably and is likely to change management in a way supported by evidence.
Recurrent Pregnancy Loss Is Different
Recurrent pregnancy loss refers to repeated pregnancies that begin but do not continue. It is not the same as recurrent implantation failure.
Evaluation may consider uterine anatomy, parental chromosomes in selected cases, genetic analysis of pregnancy tissue when available, antiphospholipid syndrome, thyroid or other medical factors, and the details of each loss.
Many early miscarriages are related to chromosomal abnormalities within the embryo, particularly as maternal age increases. In other cases, a definite cause is not identified even after appropriate evaluation.
Patients should be protected from extensive panels and treatments without proven relevance. Immune therapies, anticoagulants, or other medication should not be prescribed simply because a loss occurred.
Psychological support is an essential part of miscarriage care. The absence of a clear medical explanation does not make the grief less real.
The Role of PGT
Preimplantation genetic testing can provide useful information in selected complex cases, but its role differs according to the question being asked.
PGT-M is designed for a known single-gene condition. PGT-SR may be considered for a structural chromosomal rearrangement. PGT-A evaluates chromosome number in embryo-biopsy samples.
PGT-A may help select among several blastocysts, but it does not create chromosomally normal embryos or restore egg quality. For a patient who produces very few embryos, biopsy and testing may or may not offer an advantage over transfer, depending on age, history, embryo number, and priorities.
PGT should therefore not be presented automatically to every older patient, every low-AMH patient, or every couple after one failed cycle.
The decision requires counselling about embryo numbers, possibility of no embryo reaching biopsy, mosaic or inconclusive results, cost, freezing, and the fact that no genetic test guarantees pregnancy or a child without any health condition.
Treatment Add-Ons and the Pressure to “Try Everything”
Patients with repeated failure are especially vulnerable to treatments marketed as the missing answer.
These may include endometrial receptivity tests, immune panels, natural killer cell testing, intralipid infusions, growth hormone, platelet-rich plasma, ovarian “rejuvenation,” stem-cell procedures, microbiome tests, assisted hatching, or other laboratory and medical add-ons.
Some interventions may have a defined role in selected situations. Others remain experimental, have conflicting evidence, or have not been shown to improve live-birth outcomes for the patients to whom they are widely sold.
At Jinemed, a proposed add-on should answer four questions:
- What specific problem are we trying to solve?
- What evidence supports using this intervention in this patient?
- What are the risks, costs, and uncertainties?
- How would the treatment plan change if we did not use it?
“Nothing else worked” is not by itself scientific evidence that an unproven treatment will work.
Realistic hope requires protecting patients from both therapeutic nihilism and therapeutic excess.
Multidisciplinary Case Review
Complex fertility cases rarely belong to one discipline.
A difficult case may require input from:
- Reproductive medicine specialists
- Embryologists
- Urologists
- Genetic specialists and counsellors
- Gynaecologic surgeons
- Radiologists
- Internal medicine or endocrine specialists
- Obstetric or maternal-fetal medicine teams
- Mental-health professionals
- International patient coordinators
The purpose of multidisciplinary review is not to create more procedures. It is to combine perspectives and decide which findings are genuinely relevant.
The physician considers stimulation and reproductive history. The embryologist reconstructs laboratory development. The urologist evaluates male factors. The genetic specialist clarifies inheritance and testing. The surgeon assesses whether anatomical treatment is justified.
A coordinated plan is stronger than several disconnected specialist opinions.
International Patients with Complex Histories
International patients often contact Jinemed after multiple cycles in different clinics and countries.
Before travel, the medical file should be organised chronologically. Summary letters alone may be insufficient. Detailed stimulation charts, embryology reports, transfer records, operative notes, genetic results, ultrasound images, and sperm-retrieval reports can reveal information that a short discharge document does not contain.
The first objective is to determine what can be assessed remotely and which examinations truly require travel.
A responsible international pathway may conclude that:
- Further records are needed before making a recommendation
- A test can be completed in the home country
- A surgical issue should be addressed before IVF
- The male partner requires evaluation first
- Treatment can begin with monitoring abroad and continue in Istanbul
- Another IVF attempt is reasonable
- The expected benefit of further treatment is very limited
Good international care does not begin with booking flights. It begins with understanding the case.
When Continuing Treatment May Not Be the Best Decision
One of the hardest responsibilities in fertility care is recognising when another treatment may offer very little benefit or place an excessive burden on the patient.
Stopping, pausing, or changing direction is not the same as failure.
The decision may involve medical risk, repeated absence of eggs or embryos, genetic findings, financial limits, emotional exhaustion, relationship strain, or the patient’s changing priorities.
The role of the medical team is not to decide the patient’s life for them. It is to provide honest information about expected benefit, uncertainty, alternatives, and the consequences of continuing or stopping.
Patients should never be pressured to continue treatment to prove that they tried hard enough.
Realistic Hope
Complex cases require hope because treatment would be impossible without it. They also require realism because false promises can cause medical, emotional, and financial harm.
Realistic hope means saying:
- Your case deserves careful review.
- A low number does not define your worth or automatically eliminate every possibility.
- Previous failure provides information, but does not always predict the same outcome.
- We will distinguish established treatment from experimental options.
- We will not promise what biology cannot guarantee.
- We will tell you when the chance appears limited.
- We will respect your decision to continue, pause, or stop.
At Jinemed, experience with complex fertility cases is not measured by claiming to solve every problem. It is measured by the ability to analyse the complete journey, identify what can reasonably be changed, avoid unnecessary interventions, and remain honest when medicine reaches its limits.
That is the difference between offering treatment and providing care.